Silver Book Fact

Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used

Fact image

Hansen D, Bazell C, Pelizzari P, Pyenson B. Medicare Cost of Osteoporotic Fractures. Milliman Research Report. 2019; https://static1.squarespace.com/static/5c0860aff793924efe2230f3/t/5d76b949deb7e9086ee3d7dd/1568061771769/Medicare+Cost+of+Osteoporotic+Fractures+20190827.pdf

Reference

Title
Medicare Cost of Osteoporotic Fractures
Publication
Milliman Research Report
Publication Date
2019
Authors
Hansen D, Bazell C, Pelizzari P, Pyenson B
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value
  • Economic Value
  • Future Value

Related Facts

  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.